On 1 July, the European Commission decided to grant marketing authorisations to the company Janssen, a Johnson & Johnson company, for a vaccine against Ebola. The authorisation was granted in a month, reducing the decision-making process time in half, further demonstrating the Commission's commitment in placing the protection of public health as a priority. Commissioner Kyriakides said: “This is the second Ebola vaccine that the Commission authorises in less than a year and confirms once again that the EU remains at the forefront of the global effort to save lives from this virus.”